You might also like
BioNTech SE is a global next-generation immunotherapy company focused on developing novel medicines for cancer, infectious diseases, and other serious conditions. The company leverages the immune system's power to address diseases with unmet medical needs and significant global health burdens. BioNTech primarily sells mRNA vaccines, protein-based therapeutics, cell therapies, and small molecules.
- COVID-19 Vaccine Revenues - Generates revenue from the sale of COVID-19 vaccines, which is the major contributor to the company's revenue.
- Share of Collaboration Partners' Gross Profit - Receives a share of the gross profit from collaboration partners, primarily Pfizer, based on sales in their territories.
- Direct Product Sales to Customers - Supplies the COVID-19 vaccine directly in territories like Germany and Türkiye.
- Sales to Collaboration Partners - Manufactures and sells products to collaboration partners.
- Research & Development Revenues from Collaborations - Earns revenue from R&D collaborations.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Prof. Ugur Sahin, M.D. ExecutiveBoard | CEO and Co-Founder | None | CEO and Co-Founder of BioNTech, actively involved in strategic and operational development, particularly in oncology and COVID-19 vaccine efforts. | View Report → |
Jens Holstein Executive | Chief Financial Officer (CFO) | Non-executive board member at Veracyte Inc. | Joined BioNTech in 2021; previously CFO at MorphoSys AG and held multiple CFO/general management roles at Fresenius SE Group. | |
Ryan Richardson Executive | Chief Strategy Officer (CSO) | None | Joined BioNTech in 2018; previously worked in healthcare investment banking at J.P. Morgan and as a health economist at IMS Health. | |
Sean Marett Executive | Chief Business Officer (CBO) and Chief Commercial Officer (CCO) | Chairman of PHMR Ltd; Supervisory board member at AiCuris AG | Joined BioNTech in 2012; led commercialization of the Pfizer-BioNTech COVID-19 vaccine and negotiated key financing rounds and supply agreements. | |
Sierk Poetting, Ph.D. Executive | Chief Operating Officer (COO) | None | Joined BioNTech in 2014; previously held leadership roles at Novartis and worked as a consultant at McKinsey & Company. | |
Baroness Nicola Blackwood Board | Supervisory Board Member | Chair of Oxford University Innovation; Chair of Genomics England; Managing Director of Blackwood Intelligence Limited; Member of the House of Lords | Appointed to the Supervisory Board in 2023; brings expertise in science and innovation; holds leadership roles in prominent UK organizations. | |
Helmut Jeggle Board | Chair of the Supervisory Board | Managing Partner at Salvia GmbH; Supervisory board member at 4SC AG, Tonies SE, AiCuris AG, AFFiRiS AG, APK AG | Chair of BioNTech's Supervisory Board since 2008; instrumental in guiding the company’s strategic direction; previously held roles at Hexal AG and ATHOS KG. | |
Michael Motschmann Board | Supervisory Board Member | Co-founder and Management Board member at MIG Capital AG; Supervisory board member at APK AG, HMW Emissionshaus AG, Affiris AG; Advisory board member at Efficient Energy GmbH, Temedica GmbH, AMSilk GmbH | Supervisory Board member since 2008; co-founder of MIG Capital AG and active in venture capital investments. |
-
Although you have significant ongoing Phase II and III trials, could you elaborate on how you plan to balance the increasing R&D expenses with cost control measures, especially as you invest in assets like BNT327?
-
With regards to your updated guidance at the low end of the range due to low demand and pricing in low and middle income countries, how do you plan to mitigate these challenges and ensure revenue growth in the face of reduced COVID-19 vaccine demand?
-
Given the approximately EUR 600 million accrued for contractual disputes with licensees and collaborators this year, can you provide more clarity on the nature of these disputes and how they might impact future financials?
-
Considering the missed endpoints in the Phase III flu COVID combo program and competitors like Moderna expecting to launch their combo next year, how are you adjusting your strategy to remain competitive in the combination vaccine market?
-
As you expect to maintain or gain market share in key markets this year for your COVID-19 vaccine and believe in improved visibility into vaccine demand, how confident are you in your ability to sustain this given potential shifts in vaccination rates and market dynamics?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Biotheus | 2025 | BioNTech’s acquisition of Biotheus was aimed at strengthening its oncology portfolio with the BNT327 pan-tumor platform; the deal’s total value was $800 million in cash (plus a small portion in ADS) with up to $150 million in performance-based payments, providing full global rights to BNT327, access to an in-house antibody generation platform, and a new R&D hub and manufacturing facility as an indirect Chinese subsidiary. |
InstaDeep | 2023 | BioNTech’s acquisition of InstaDeep involved buying 100% of the remaining shares for approximately €500 million, structured with cash, BioNTech shares, and milestone-based payments, to integrate AI/ML capabilities across industries while InstaDeep continues as a UK-based global subsidiary. |
Medigene | 2022 | In 2022, BioNTech collaborated with and acquired key assets from Medigene, including its next-generation preclinical TCR program (PRAME TCR) and licenses to the PD1-41BB switch receptor, for an upfront payment of EUR 26 million plus milestone, regulatory, and commercial payments, thereby securing exclusive worldwide rights to further TCR immunotherapies. |
Recent press releases and 8-K filings for BNTX.
- Investment Announcement: BioNTech SE’s subsidiary, BioNTech UK Ltd., signed a grant agreement with the UK Government to expand its R&D activities in the UK.
- Financial Commitment: The company committed to invest up to £1 billion over the next 10 years, while the UK Government will provide a grant of up to £129 million over the same period.
- Strategic Expansion: The funds will support the establishment of two new R&D centers (including one in Cambridge), the setup of a UK headquarters in London with an integrated AI hub, and the acceleration of clinical trials.
- Strategic expansion: Acquired Biotheus to secure full global rights for the antibody candidate BNT327, accelerating oncology development .
- Oncology pipeline advancement: Over 20 product candidates in Phase II/III studies, including mRNA cancer immunotherapies (FixVac and iNeST) and bispecific antibodies , .
- COVID-19 vaccine success: Delivered over 4.9 billion doses; planning variant-adapted vaccines for the 2025-2026 season .
- Robust financial foundation: Maintained a strong balance sheet with approximately EUR 2.8 billion in 2024 despite shifting COVID-19 demand .
- Operational & Financial Outlook: Q1 2025 performance review and 2025 outlook under the leadership of CEO Prof. Dr. Ugur Sahin, highlighting progress through fiscal 2024 and Q1 2025 .
- BioNTech reported Q1 2025 revenues of EUR 183 million [0,4] with a net loss of EUR 460 million (loss per share €1.73 ).
- Maintained robust liquidity with €15.9 bn in cash, cash equivalents & security investments [0,6,7].
- Provided full-year revenue guidance of EUR 1.7–2.2 billion .
- Advancing the oncology portfolio with BNT327 in Phase II/III trials for SCLC, TNBC and promising Phase 2 data in NSCLC [1,2,6,8].
- Strengthening its COVID-19 strategy with preparations for a variant-adapted vaccine [0,3] and sustaining >50% global market share for COMIRNATY .
- Corporate updates include the acquisition of Biotheus and the appointment of Ramón Zapata-Gomez as CFO effective July 1, 2025 [1,6,7,8].
- BioNTech SE will present clinical and preclinical data from its oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the AACR Annual Meeting in Chicago from April 25-30, 2025.
- The presentations include first clinical data for the combination of the PD-L1xVEGF-A bispecific antibody candidate BNT327 with ADCs and results from a Phase 1 trial of the mRNA cancer immunotherapy candidate BNT116 in advanced NSCLC patients.
- Balance Sheet Profit Resolution: The management proposes carrying forward the full EUR 8,232,460,140.27 balance sheet profit from FY 2024.
- Board and Auditor Approvals: Resolutions include approving the actions of the Management and Supervisory Boards for FY 2024 and appointing EY as auditor for FY 2025, covering interim and sustainability reporting.
- Capital Increase Authorization: The company plans to cancel the existing Authorized Capital 2021 and establish new Authorized Capital 2025 amounting to EUR 124,276,100, with provisions to exclude subscription rights under certain conditions.
- On December 23, 2024, BioNTech SE entered into a binding term sheet with the University of Pennsylvania to secure license rights under certain Penn patents for the development and commercialization of licensed products.
- On March 27, 2025, the Company and Penn executed a Settlement Agreement that includes potential payments up to $467.0 million, comprising royalties, funding for a three-year research term extension, and a contribution to an R&D investment fund.
- Additional agreements include a side letter establishing a low single-digit royalty on net sales from 2024 onward, along with amendments to existing collaboration and license agreements.
- Financial Performance: In Q4 2024, BioNTech recorded approximately EUR 1.2 billion in quarterly revenue and a full-year revenue of around EUR 2.8 billion, with a net loss of EUR 665 million driven by reduced COVID-19 vaccine demand and contractual dispute impacts.
- 2025 Guidance: The company expects revenues between EUR 1.7 billion and EUR 2.2 billion in 2025 and plans to increase R&D expenditures to EUR 2.6–2.8 billion to support its expanding oncology pipeline.
- Strategic Initiatives: BioNTech is advancing key oncology programs—including BNT327 and mRNA cancer immunotherapies—through multiple Phase II/III trials and has bolstered its strategic positioning with the recently completed acquisition of Biotheus.
- Strong financial performance in Q4 2024 with €1,190m in total revenues for the quarter and full-year revenues reaching €2,751m, alongside a reported diluted loss per share of €(2.77).
- The company maintained a robust balance sheet with €17.4bn in cash and security investments, underscoring its strong liquidity position.
- Significant advancements were made in the oncology portfolio, especially with mRNA cancer immunotherapies and multiple ongoing Phase 2 trials for BNT327 targeting indications such as SCLC, TNBC, and NSCLC.
- Financial Performance: Reported Q4 revenues of approximately €1.2 billion and full year revenues of about €2.8 billion, with a reported full year net loss of €0.7 billion and diluted loss per share of €2.77.
- Liquidity and Investments: Maintained a strong balance sheet with €17.4 billion in cash, cash equivalents, and security investments as of December 31, 2024.
- Oncology Pipeline and Outlook: Advanced its oncology portfolio through over 20 active Phase 2 and Phase 3 clinical trials, completed the acquisition of Biotheus to secure full control of the BNT327 candidate, and provided 2025 revenue guidance between €1.7 billion and €2.2 billion.